|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C23H35O7.Na |
|||
| Molecular Weight | 446.51 | CAS No. | 81131-70-6 | |
| Solubility (25°C)* | In vitro | DMSO | 89 mg/mL (199.32 mM) | |
| Water | 89 mg/mL (199.32 mM) | |||
| Ethanol | 45 mg/mL (100.78 mM) | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Pravastatin sodium (CS-514) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro | Pravastatin-Na at 10 μM inhibits the sterol synthesis at a level greater than 50% in PBMC. [1] Pravastatin produces relaxation of isolated aortic rings, with maximum vasorelaxations of 62.8% at 10 μM and latency of ~8 min. Pravastatin (< 10 μM) stimulates NOS activity and NO release within 10 min in cultured bovine aortic endothelial cells. L-arginine potentiates NO production in response to Pravastatin (< 10 μM) in cultured bovine aortic endothelial cells. [2] Pravastatin results in a dose-dependent inhibition of macrophage cholesterol synthesis in human monocyte derived macrophages(HMDM), mouse peritoneal macrophages (MPM) and a J-774 A.1 macrophagelike cell lines. Small concentrations of pravastatin (< 0.19 μg/mL) increases the cellular cholesterol esterification rate after incubation with LDL, but higher concentrations (< 100 μg/mL) results in an inhibition of the esterification. [3] Pravastatin (< 0.5 mM) decreases Rho/ROCK pathway activity in human colon and ileum explants, which leads to decreased CCN2 mRNA levels. Pravastatin (<1 mM) also induces CCN2 inhibition in primary human smooth muscle cells. Pravastatin (< 0.5 mM) decreases type I collagen and fibronectin mRNA levels in both human colon and ileum explants and primary human smooth muscle cells. [4] | ||
| In vivo | Pravastatin (40 mg, single dose) causes a reduction in cholesterol synthesis in human monocyte derived macrophages by 62% in healthy subjects and 47% in hypercholesterolaemic patients. Pravastatin (40 mg/day, 8 weeks) results in a 55% inhibition of cholesterol synthesis and a 57% increase in LDL degradation in hypercholesterolaemic patients. [3] Pravastatin (30 mg/kg/d) results in decreased length of the dystrophic lesions by 34% and recovery of muscular structure in Male Wistar rats receiving irradiation, associated with decreased CCN2 level. [4] |
Protocol (from reference)
| Animal Study:[4] |
|
|---|
References
Customer Product Validation
-
, , JAMA Oncol, 2015, 1(4):495-504.
Selleck's Pravastatin sodium has been cited by 8 publications
| Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II [ Int J Mol Sci, 2023, 24(7)6500] | PubMed: 37047470 |
| Simvastatin cream alleviates dermal fibrosis in a rabbit ear hypertrophic scar model [ J Cosmet Dermatol, 2022, 10.1111/jocd.15142] | PubMed: 35665590 |
| Ultra-fast proteomics with Scanning SWATH [ Nat Biotechnol, 2021, 10.1038/s41587-021-00860-4] | PubMed: 33767396 |
| Classic and Targeted Anti-Leukaemic Agents Interfere With the Cholesterol Biogenesis Metagene in Acute Myeloid Leukaemia: Therapeutic Implications [ J Cell Mol Med, 2020, 25] | PubMed: 32450611 |
| Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer [Kou X Cancer Sci, 2018, 109(10):3272-3284] | PubMed: 30039622 |
| Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation [Kou X Eur J Pharmacol, 2017, 813:161-171] | PubMed: 28826913 |
| The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer [Harshman LC Prostate, 2017, 77(13):1303-1311] | PubMed: 28762529 |
| Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. [Harshman LC, et al. JAMA Oncol, 2015, 10.1001/jamaoncol.2015.0829] |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.